Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clare L Scott

Showing results (61-70 of 110) with videos related to

Pageof 11
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2024
Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase InhibitorAngelina Tjokrowidjaja, M L Friedlander, Jonathan A Ledermann, et al.
JCO Clinical Cancer Informatics|February 22, 2020
CART-WHEEL.org: An Ethically Approved Online Database for Patient-Entered Data to Facilitate Rare Cancer ResearchDamien Kee, Clare Parker, Susie Bae, et al.
Blood|September 11, 2010
Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also BimLina Happo, Mark S Cragg, Belinda Phipson, et al.
Cancer|March 19, 2021
Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysisChee Khoon Lee, Michael L Friedlander, Angelina Tjokrowidjaja, et al.
Reproduction (Cambridge, England)|May 27, 2014
PUMA regulates germ cell loss and primordial follicle endowment in miceMichelle Myers, F Hamish Morgan, Seng H Liew, et al.
JCO Oncology Practice|January 14, 2026
Quality Matters: Linking Patterns of Care to Ovarian Cancer Survival in a National Gynae-Oncology RegistryMahendra Naidoo, Orla McNally, Clare L Scott, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 19, 2025
Patterns of care and development of quality indicators in patients with non-epithelial and rare ovarian tumors in Australia: insights from the National Gynae-Oncology RegistryYeh Chen Lee, Aleesha Whitely, Michael Burling, et al.
British Journal of Cancer|May 2, 2022
BRCA mutations lead to XIAP overexpression and sensitise ovarian cancer to inhibitor of apoptosis (IAP) family inhibitorsMattia Cremona, Cassandra J Vandenberg, Angela M Farrelly, et al.
Cancer Cell|November 14, 2006
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralizedMark F van Delft, Andrew H Wei, Kylie D Mason, et al.
American Journal of Hematology|March 23, 2021
WhiMSICAL: A global Waldenström's Macroglobulinemia patient-derived data registry capturing treatment and quality of life outcomesIbrahim Tohidi-Esfahani, Andrew Warden, Elena Malunis, et al.
Pageof 11

Showing results (61-70 of 110) with videos related to

Sort By:
Pageof 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2024
Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase InhibitorAngelina Tjokrowidjaja, M L Friedlander, Jonathan A Ledermann, et al.
JCO Clinical Cancer Informatics|February 22, 2020
CART-WHEEL.org: An Ethically Approved Online Database for Patient-Entered Data to Facilitate Rare Cancer ResearchDamien Kee, Clare Parker, Susie Bae, et al.
Blood|September 11, 2010
Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also BimLina Happo, Mark S Cragg, Belinda Phipson, et al.
Cancer|March 19, 2021
Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysisChee Khoon Lee, Michael L Friedlander, Angelina Tjokrowidjaja, et al.
Reproduction (Cambridge, England)|May 27, 2014
PUMA regulates germ cell loss and primordial follicle endowment in miceMichelle Myers, F Hamish Morgan, Seng H Liew, et al.
JCO Oncology Practice|January 14, 2026
Quality Matters: Linking Patterns of Care to Ovarian Cancer Survival in a National Gynae-Oncology RegistryMahendra Naidoo, Orla McNally, Clare L Scott, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 19, 2025
Patterns of care and development of quality indicators in patients with non-epithelial and rare ovarian tumors in Australia: insights from the National Gynae-Oncology RegistryYeh Chen Lee, Aleesha Whitely, Michael Burling, et al.
British Journal of Cancer|May 2, 2022
BRCA mutations lead to XIAP overexpression and sensitise ovarian cancer to inhibitor of apoptosis (IAP) family inhibitorsMattia Cremona, Cassandra J Vandenberg, Angela M Farrelly, et al.
Cancer Cell|November 14, 2006
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralizedMark F van Delft, Andrew H Wei, Kylie D Mason, et al.
American Journal of Hematology|March 23, 2021
WhiMSICAL: A global Waldenström's Macroglobulinemia patient-derived data registry capturing treatment and quality of life outcomesIbrahim Tohidi-Esfahani, Andrew Warden, Elena Malunis, et al.
Pageof 11